Contact
OncoMed
Targeting the pathways critical to cancer stem cells
In December 2007, OncoMed and GSK announced a broad discovery, development and commercialization collaboration covering up to nine programs against novel cancer stem cell targets for oncology indications. The ceedd's alliance with OncoMed, has established a diverse pipeline of monoclonal antibodies to target multiple pathways important to the activity of cancer stem cells. This collaboration further confirms GSK's position as a world leader in the development of new oncology medicines and our commitment to support highly innovative approaches in this area.
"GSK came into this agreement respecting our accomplishments as a small discovery-based company. That attitude, along with our respect for GSK's resources and experience, played a major role in determining that the ceedd structure was the right one for us. They are bringing world-respected scientists to the table to be part of our collaboration, and their experience has already added real and measurable value for OncoMed."
Paul Hastings
President and Chief Executive Officer, OncoMed, Inc.